๐”– Scriptorium
โœฆ   LIBER   โœฆ

๐Ÿ“

Improving the Utility and Translation of Animal Models for Nervous System Disorders: Workshop Summary

โœ Scribed by Forum on Neuroscience and Nervous System Disorders, Board on Health Sciences Policy, Institute of Medicine, Diana E. Pankevich, Theresa M. Wizemann, Bruce M. Altevogt


Publisher
National Academies Press
Year
2013
Tongue
English
Leaves
110
Category
Library

โฌ‡  Acquire This Volume

No coin nor oath required. For personal study only.

โœฆ Synopsis


Nervous system diseases and disorders are highly prevalent and substantially contribute to the overall disease burden. Despite significant information provided by the use of animal models in the understanding of the biology of nervous system disorders and the development of therapeutics; limitations have also been identified. Treatment options that are high in efficacy and low in side effects are still lacking for many diseases and, in some cases are nonexistent. A particular problem in drug development is the high rate of attrition in Phase II and III clinical trials. Why do many therapeutics show promise in preclinical animal models but then fail to elicit predicted effects when tested in humans?

On March 28 and 29, 2012, the Institute of Medicine Forum on Neuroscience and Nervous System Disorders convened the workshop "Improving Translation of Animal Models for Nervous System Disorders" to discuss potential opportunities for maximizing the translation of new therapies from animal models to clinical practice. The primary focus of the workshop was to examine mechanisms for increasing the efficiency of translational neuroscience research through discussions about how and when to use animal models most effectively and then best approaches for the interpretation of the data collected. Specifically, the workshop objectives were to: discuss key issues that contribute to poor translation of animal models in nervous system disorders, examine case studies that highlight successes and failures in the development and application of animal models, consider strategies to increase the scientific rigor of preclinical efficacy testing, explore the benefits and challenges to developing standardized animal and behavioral models. Improving the Utility and Translation of Animal Models for Nervous System Disorders: Workshop Summary also identifies methods to facilitate development of corresponding animal and clinical endpoints, indentifies methods that would maximize bidirectional translation between basic and clinical research and determines the next steps that will be critical for improvement of the development and testing of animal models of disorders of the nervous system.

โœฆ Table of Contents


Cover......Page 1
C: Registered Attendees......Page 0
ยฉ......Page 3
Reviewers......Page 10
Contents......Page 12


๐Ÿ“œ SIMILAR VOLUMES


Improving and Accelerating Therapeutic D
โœ Institute of Medicine; Board on Health Sciences Policy; Forum on Neuroscience an ๐Ÿ“‚ Library ๐Ÿ“… 2014 ๐Ÿ› National Academies Press ๐ŸŒ English

Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop part

Glutamate-Related Biomarkers in Drug Dev
โœ Forum on Neuroscience and Nervous System Disorders, Institute of Medicine of the ๐Ÿ“‚ Library ๐Ÿ“… 2011 ๐Ÿ› The National Academies Press ๐ŸŒ English

Glutamate is the most pervasive neurotransmitter in the central nervous system (CNS). Despite this fact, no validated biological markers, or biomarkers, currently exist for measuring glutamate pathology in CNS disorders or injuries. Glutamate dysfunction has been associated with an extensive range o

Therapeutic Development in the Absence o
โœ and Medicine Engineering National Academies of Sciences; Health and Medicine Div ๐Ÿ“‚ Library ๐Ÿ“… 2017 ๐Ÿ› National Academies Press ๐ŸŒ English

Compared with other disease areas, central nervous system (CNS) disorders have had the highest failure rate for new compounds in advanced clinical trials. Most CNS drugs fail because of efficacy, and the core issue underlying these problems is a poor understanding of disease biology. Concern about t

Improving the Efficiency and Effectivene
โœ Institute of Medicine; Board on Health Sciences Policy; Roundtable on Translatin ๐Ÿ“‚ Library ๐Ÿ“… 2014 ๐Ÿ› National Academies Press ๐ŸŒ English

The process for translating basic science discoveries into clinical applications has historically involved a linear and lengthy progression from initial discovery to preclinical testing, regulatory evaluation and approval, and, finally, use in clinical practice. The low rate of translation from basi

Financial Incentives to Encourage Develo
โœ Institute of Medicine; Board on Health Sciences Policy; and Translation Developm ๐Ÿ“‚ Library ๐Ÿ“… 2015 ๐Ÿ› National Academies Press ๐ŸŒ English

The Institute of Medicine (IOM) Forum on Neuroscience and Nervous System Disorders, in collaboration with the IOM Forum on Drug Discovery, Development, and Translation, convened a workshop on January 20-21, 2015, to explore policy changes that might increase private sector investment in research and

Harnessing Mobile Devices for Nervous Sy
โœ and Medicine Engineering National Academies of Sciences; Health and Medicine Div ๐Ÿ“‚ Library ๐Ÿ“… 2019 ๐Ÿ› National Academies Press ๐ŸŒ English

The critical importance of using mobile technology is clear to anyone in the health professions, particularly those who treat people with central nervous system (CNS) disorders. To explore current developments and opportunities for using mobile technology to advance research and treatment of CNS dis